Injection site pain: FDA reporting patterns
299,521 FDA FAERS reports mention Injection site pain. 46,470 reports have a serious outcome flag.
Medicines named as suspect
- Etanercept: 56,982 reports
- Adalimumab: 50,918 reports
- Dupilumab: 36,629 reports
- Tirzepatide: 13,493 reports
- Evolocumab: 10,747 reports
- Dulaglutide: 9,707 reports
- Galcanezumab: 7,509 reports
- Exenatide: 6,714 reports
- Interferon Beta-1a: 6,271 reports
- Glatiramer: 5,567 reports
- Leuprolide: 5,083 reports
- Teriparatide: 4,728 reports
FAERS reports describe events reported after a medicine was taken. They do not prove that the medicine caused an event, measure how often a side effect occurs, or estimate personal risk.
Source: FDA FAERS via openFDA. FAERS data through 2026-06-30. Sources, methods, and limitations.